Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
about
Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studiesIs the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisType-2 diabetes: Current understanding and future perspectivesRegulation of energy balance by inflammation: common theme in physiology and pathologySomething old, something new and something very old: drugs for treating type 2 diabetesRegulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazoneTreatment of nonalcoholic fatty liver disease: role of AMPK.The inflammatory gene pathway is not a major contributor to polycystic ovary snydrome.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controlsRisk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study.Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.Anti-inflammatory therapies for cardiovascular diseaseA favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Inflammation, metaflammation and immunometabolic disorders.Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies.Sustained NF-κB activation and inhibition in β-cells have minimal effects on function and islet transplant outcomesSalsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanicsP65 inactivation in adipocytes and macrophages attenuates adipose inflammatory response in lean but not in obese mice.Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor κB.Nutrition and metabolic correlates of obesity and inflammation: clinical considerations.LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus.Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity.Novel Agents for the Treatment of Type 2 Diabetes.Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individualsLPS-induced NFκB enhanceosome requires TonEBP/NFAT5 without DNA binding.Renal Toxicity Associated with Salsalate in Elderly Adults with AnemiaStrategies and Challenges in Clinical Trials Targeting Human Aging.Effect of Treatment with Salsalate, Menhaden Oil, Combination of Salsalate and Menhaden Oil, or Resolvin D1 of C57Bl/6J Type 1 Diabetic Mouse on Neuropathic Endpoints.Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).Macrophages, fat, and the emergence of immunometabolism.Inflammation as a Therapeutic Target for Diabetic Neuropathies.The effect of salsalate therapy on endothelial function in a broad range of subjects.The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes.Regulation of hepatocyte growth factor expression by NF-κB and PPARγ in adipose tissue.
P2860
Q24562012-B2DFBF4A-654B-490A-B312-7D4C89A0C8D6Q26746659-01FFA902-8DF9-4E97-9E33-B819A34A572CQ26801324-76F4EA07-0A7E-40CC-BC81-69BCBA76713FQ26829584-9F6CF913-782F-4108-8281-583841C475BBQ26865663-48A8D614-C758-47F2-A667-0132056C1E17Q28537905-87761D06-3BA8-4298-804A-DBA1D9937D7EQ30248230-2F414634-F03D-4D95-9CBB-8C59F1B95D9DQ30407754-8CBEF744-57A7-4243-A3BA-081CA64AB80EQ30597265-02CED7CD-3D49-4F0B-B141-89E171DE6B56Q33620560-9021C098-44A1-43B4-91AD-F3E6539C0F86Q33769258-417E7B36-0832-4667-9497-589497C9CBDBQ33838440-1B42546B-DD85-49CE-B083-A2B50BC4C8FDQ33844872-82CFF25B-E1CF-4FB6-8992-15ADA3276F54Q34137872-1EA4717C-6621-48AB-9941-9A81F33AB984Q34389286-2B35FC1F-EA08-412A-9A25-D37594237A64Q34444895-7B0701D9-9BE4-47D6-B350-15A0F14CB272Q34550852-5F8E3E23-73D8-48A8-AE13-563DBA74B857Q34773899-512B6C71-05A2-4835-A0C0-EF775B6F4CFCQ35035258-6EF0E3C7-08ED-4ACB-A446-D9B862C888AAQ35122399-42F89B1E-01A1-4BA0-A500-BBB3A2051B2DQ35178548-A347F8EE-B344-4A19-B065-AC3D119C28B7Q35534914-13F02DFE-F595-4E59-B355-5AEDCEBE184FQ35540750-2795616D-82CE-4849-9274-CF06AF67843EQ35600641-6E5102DD-46DB-4EDA-9C17-A0843C7159E4Q35637841-A763A84B-6A6B-48E6-841F-B6BEA3B23567Q35894344-70BE66BD-52CA-4B1C-9211-21C1A20CF445Q35910421-C28B9BC9-9964-41A6-B535-DCDE9C25F2CBQ36124070-A783B984-B056-4561-9E41-751AEBB7404DQ36841546-FA057B3C-0167-4D7B-A753-E483AC19432CQ36890786-1307D2A8-5635-4652-9965-89E89202F3CBQ37322080-12FBC1BA-AC0C-4D84-945A-781BA783D984Q37330126-E1B9DCFF-6D14-48BF-95EA-AE56AE75F358Q37331296-AD7C2DFB-99EB-4742-8435-D03D75A2878FQ37384085-26DCFF2E-CE3F-4AAE-86E1-A80282256E2AQ37450547-18F3A98C-6AFF-4E10-8A2E-E8E3DB4CD50FQ37648486-A9A3400C-E6FA-45FC-B782-E986C3E700CFQ37660885-C353574B-CEFA-4F7A-A6A0-850CF93C8E9CQ37672638-19FF2A00-1E0A-4C76-9FF8-9335D0CE0DDFQ37686096-3F494003-E9AB-40C9-B761-01A1FE4FF4FEQ37707637-36A2D1AE-EB8C-475C-BD9F-E9C6681987FB
P2860
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@ast
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@en
Salicylate
@nl
type
label
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@ast
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@en
Salicylate
@nl
prefLabel
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@ast
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@en
Salicylate
@nl
P2093
P2860
P1476
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
@en
P2093
Kathleen A Jablonski
Laura Tipton
Myrlene A Staten
Steven E Shoelson
Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team
Vivian Fonseca
Yii-Der Ida Chen
P2860
P356
10.7326/0003-4819-159-1-201307020-00003
P407
P577
2013-07-01T00:00:00Z